- Home
- MKZR vs TOVX Comparison
MKZR vs TOVX Comparison
Compare MKZR & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MKZR | TOVX |
|---|---|---|
| Founded | 2012 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6M | 7.3M |
| IPO Year | N/A | 2006 |
Fundamental Metrics
Financial Performance| Metric | MKZR | TOVX |
|---|---|---|
| Price | $3.75 | $0.17 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 41.8K | ★ 2.7M |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | ★ 26.45% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $20,994,778.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 3.63 | N/A |
| 52 Week Low | $3.26 | $0.18 |
| 52 Week High | $50.00 | $2.08 |
Technical Indicators
Market Signals| Indicator | MKZR | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 41.73 | 35.57 |
| Support Level | $3.65 | $0.21 |
| Resistance Level | $5.00 | $0.24 |
| Average True Range (ATR) | 0.44 | 0.03 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 19.77 | 9.33 |
Price Performance
Historical ComparisonAbout MKZR MacKenzie Realty Capital Inc.
Mackenzie Realty Capital Inc is a company which is a Real estate investment trust (REIT). The company has one reportable segment, income-producing real estate properties which consists of activities related to investing in real estate. It is a real estate investment manager who utilizes an approach to real estate securities, often seeing opportunities that others overlook. Based in Orinda, California, MacKenzie Capital Management has specialized in discounted real estate securities and asset management.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.